Targeted therapies for kidney cancer in urologic practice
Targeted therapies for kidney cancer in urologic practice
复制标题
DOI：
10.1016/j.urolonc.2007.05.009
复制
发表时间：
2007-09-01
影响因子：
2.7
通讯作者：
Uzzo, Robert G.
中科院分区：
文献类型：
--
作者：
Haas, Naomi B.;Uzzo, Robert G.
肾细胞癌（RCC）是所有泌尿生殖系统恶性肿瘤中最致命的，近一半的患者表现为局部晚期或转移性疾病。历史上，全身治疗如化疗或免疫治疗的总有效率为5-15%，且很少有持久的反应。新批准的更有效的靶向治疗转移性RCC的基础是基于对引起RCC的分子机制的基本知识。我们回顾了RCC靶向治疗的临床数据，并讨论了相关的生物学、副作用和对临床医生重要的靶点。(C) 2007爱思唯尔公司版权所有。
Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician. (C) 2007 Elsevier Inc. All rights reserved.